Multiple choices for HIV therapy with integrase strand transfer inhibitors

Multiple choices for HIV therapy with integrase strand transfer inhibitors

<p>Abstract</p> <p>Two integrases inhibitors, raltegravir and elvitegravir, have now been approved by regulatory agencies for use in the treatment of HIV-infected patients; and the approval of a third such drug, dolutegravir, is expected during 2013 on the basis of several phase 3...

Full description

Bibliographic Details
Main Authors: Raffi Francois, Wainberg Mark A
Format: Article
Language:English
Published: BMC 2012-12-01
Series:Retrovirology
Subjects:
Raltegravir
Elvitegravir
Dolutegravir
Integrase strand transfer inhibitors
Online Access:http://www.retrovirology.com/content/9/1/110
id doaj-eb650a3a39cb41e58ca6abe4682b059b
record_format Article
spelling doaj-eb650a3a39cb41e58ca6abe4682b059b2020-11-25T00:25:07ZengBMCRetrovirology1742-46902012-12-019111010.1186/1742-4690-9-110Multiple choices for HIV therapy with integrase strand transfer inhibitorsRaffi FrancoisWainberg Mark A<p>Abstract</p> <p>Two integrases inhibitors, raltegravir and elvitegravir, have now been approved by regulatory agencies for use in the treatment of HIV-infected patients; and the approval of a third such drug, dolutegravir, is expected during 2013 on the basis of several phase 3 clinical trials. The advent of this new class of antiretroviral (ARV) medications represents a major advance in the management of HIV infection, and each of these three drugs can be expected to continue to be an important component of ARV combination regimens.</p> http://www.retrovirology.com/content/9/1/110RaltegravirElvitegravirDolutegravirIntegrase strand transfer inhibitors
collection DOAJ
language English
format Article
sources DOAJ
author Raffi Francois
Wainberg Mark A
spellingShingle Raffi Francois
Wainberg Mark A
Multiple choices for HIV therapy with integrase strand transfer inhibitors
Retrovirology
Raltegravir
Elvitegravir
Dolutegravir
Integrase strand transfer inhibitors
author_facet Raffi Francois
Wainberg Mark A
author_sort Raffi Francois
title Multiple choices for HIV therapy with integrase strand transfer inhibitors
title_short Multiple choices for HIV therapy with integrase strand transfer inhibitors
title_full Multiple choices for HIV therapy with integrase strand transfer inhibitors
title_fullStr Multiple choices for HIV therapy with integrase strand transfer inhibitors
title_full_unstemmed Multiple choices for HIV therapy with integrase strand transfer inhibitors
title_sort multiple choices for hiv therapy with integrase strand transfer inhibitors
publisher BMC
series Retrovirology
issn 1742-4690
publishDate 2012-12-01
description <p>Abstract</p> <p>Two integrases inhibitors, raltegravir and elvitegravir, have now been approved by regulatory agencies for use in the treatment of HIV-infected patients; and the approval of a third such drug, dolutegravir, is expected during 2013 on the basis of several phase 3 clinical trials. The advent of this new class of antiretroviral (ARV) medications represents a major advance in the management of HIV infection, and each of these three drugs can be expected to continue to be an important component of ARV combination regimens.</p>
topic Raltegravir
Elvitegravir
Dolutegravir
Integrase strand transfer inhibitors
url http://www.retrovirology.com/content/9/1/110
work_keys_str_mv AT raffifrancois multiplechoicesforhivtherapywithintegrasestrandtransferinhibitors
AT wainbergmarka multiplechoicesforhivtherapywithintegrasestrandtransferinhibitors
_version_ 1725350029887012864

Similar Items